UM

Browse/Search Results:  1-10 of 12 Help

Selected(0)Clear Items/Page:    Sort:
TNFR2 deficiency impairs the growth of mouse colon cancer Journal article
Li,Ping, Yang,Yang, Yang,Xinyu, Wang,Yifei, Chou,Chon Kit, Jiang,Mengmeng, Zheng,Jingbin, Chen,Fengyang, Chen,Xin*. TNFR2 deficiency impairs the growth of mouse colon cancer[J]. International Journal of Biological Sciences, 2023, 19(4), 1024-1035.
Authors:  Li,Ping;  Yang,Yang;  Yang,Xinyu;  Wang,Yifei;  Chou,Chon Kit; et al.
Favorite | TC[WOS]:8 TC[Scopus]:7  IF:8.2/8.3 | Submit date:2023/08/03
Tumor Necrosis Factor (Tnf)  Tumor Necrosis Factor Receptor Type Ii (Tnfr2)  Colon Cancer  Cancer Immunotherapy  
Preferential Expansion of CD4+Foxp3+ Regulatory T Cells (Tregs) In Vitro by Tumor Necrosis Factor Book chapter
出自: T-Cell Receptor Signaling:Humana, New York, NY, 2020, 页码:71-78
Authors:  Chon-Kit Chou;  Xin Chen
Favorite | TC[WOS]:1 TC[Scopus]:1 | Submit date:2021/03/01
Cd4++++ Foxp3++++ Regulatory t Cells (Tregs)  Cfse Cell Division Assay  Flow Cytometry  Selective Expansion  Tnf Receptor 2 (Tnfr2)  Tumor Necrosis Factor (Tnf)  
The p38 MAPK inhibitor SB203580 abrogates tumor necrosis factor-induced proliferative expansion of mouse CD4+Foxp3+ regulatory T cells Journal article
He T., Liu S., Chen S., Ye J., Wu X., Bian Z., Chen X.. The p38 MAPK inhibitor SB203580 abrogates tumor necrosis factor-induced proliferative expansion of mouse CD4+Foxp3+ regulatory T cells[J]. Frontiers in Immunology, 2018, 9(JUL).
Authors:  He T.;  Liu S.;  Chen S.;  Ye J.;  Wu X.; et al.
Favorite | TC[WOS]:34 TC[Scopus]:34 | Submit date:2018/11/06
cd4+foxp3+ Regulatory t Cells  P38 Mapk  Proliferation  Tnf Receptor Type Ii  Tumor Necrosis Factor  
The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells Journal article
He, Tianzhen, Liu, Shuoyang, Chen, Shaokui, Ye, Jingyi, Wu, Xueqiang, Bian, Zhaoxiang, Chen, Xin. The p38 MaPK inhibitor sB203580 abrogates Tumor necrosis Factor-induced Proliferative expansion of Mouse cD4(+)Foxp3(+) regulatory T cells[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9.
Authors:  He, Tianzhen;  Liu, Shuoyang;  Chen, Shaokui;  Ye, Jingyi;  Wu, Xueqiang; et al.
Favorite | TC[WOS]:34 TC[Scopus]:34  IF:5.7/6.8 | Submit date:2018/10/30
Tumor Necrosis Factor  Tnf Receptor Type Ii  P38 Mapk  Cd4(+)Foxp3(+) Regulatory t Cells  Proliferation  
TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders Journal article
Shaikh, Faraz, He, Jiang, Bhadra, Pratiti, Chen, Xin, Siu, Shirley W., I. TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9.
Authors:  Shaikh, Faraz;  He, Jiang;  Bhadra, Pratiti;  Chen, Xin;  Siu, Shirley W., I
Favorite | TC[WOS]:16 TC[Scopus]:19  IF:5.7/6.8 | Submit date:2018/10/30
Tnf Receptor Type Ii  Tnf  Regulatory t Cells  Virtual Screening  Drug Discovery  Mm-pbsa  
TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders Journal article
Shaikh F., He J., Bhadra P., Chen X., Siu S.W.. TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: Current perspectives and in silico search for small molecule binders[J]. Frontiers in Immunology, 2018, 9(JUN).
Authors:  Shaikh F.;  He J.;  Bhadra P.;  Chen X.;  Siu S.W.
Favorite | TC[WOS]:16 TC[Scopus]:19 | Submit date:2019/04/04
Drug Discovery  Mm-pbsa  Regulatory t Cells  Tnf  Tnf Receptor Type Ii  Virtual Screening  
Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents Journal article
Zou, Huimin, Li, Ruixin, Hu, Hao, Hu, Yuanjia, Chen, Xin. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9.
Authors:  Zou, Huimin;  Li, Ruixin;  Hu, Hao;  Hu, Yuanjia;  Chen, Xin
Favorite | TC[WOS]:46 TC[Scopus]:49  IF:5.7/6.8 | Submit date:2018/10/30
Tnf Receptor Type Ii  Regulatory t Cells  Tnf Receptor Type Ii Agonists  Tnf Receptor Type Ii Antagonists  Immunotherapy  
Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics Journal article
Li,Ping, Zheng,Ying, Chen,Xin. Drugs for autoimmune inflammatory diseases: From small molecule compounds to anti-TNF biologics[J]. Frontiers in Pharmacology, 2017, 8(JUL).
Authors:  Li,Ping;  Zheng,Ying;  Chen,Xin
Favorite | TC[WOS]:235 TC[Scopus]:160  IF:4.4/5.0 | Submit date:2021/03/01
Anti-tnf Biologics  Autoimmune Inflammatory Diseases  Non-steroidal Anti-inflammatory Drugs (Nsaids)  Tnf Receptor  Tumor Necrosis Factor Alpha (Tnf)  
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics Journal article
Li, Ping, Zheng, Ying, Chen, Xin. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics[J]. FRONTIERS IN PHARMACOLOGY, 2017, 8.
Authors:  Li, Ping;  Zheng, Ying;  Chen, Xin
Favorite | TC[WOS]:235 TC[Scopus]:161  IF:4.4/5.0 | Submit date:2018/10/30
Tumor Necrosis Factor Alpha (Tnf)  Autoimmune Inflammatory Diseases  Non-steroidal Anti-inflammatory Drugs (Nsaids)  Anti-tnf Biologics  Tnf Receptor  
In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Journal article
Zhou, Q., Hu, Y., Howard, O., Oppenheim, J., Chen, X.. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.[J]. Cytokine, 2014, 56-64.
Authors:  Zhou, Q.;  Hu, Y.;  Howard, O.;  Oppenheim, J.;  Chen, X.
Favorite |   IF:3.7/3.5 | Submit date:2022/08/30
FoxP3  IL-2  KI  KO  Regulatory T cell  TNF  TNFR2  TNFR2 Fc fusion protein  TNFR2-Fc  Teffs  Th17  Tregs  effector T cells  forkhead box P3  knock in  knock out  nCD4  naïve CD4 cells  regulatory T cells  tumor necrosis factor receptor type II